NASDAQ:NVLN - Novelion Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.34 -0.02 (-1.47 %)
(As of 02/18/2019 03:28 AM ET)
Previous Close$1.34
Today's Range$1.33 - $1.3932
52-Week Range$0.70 - $5.32
Volume206,192 shs
Average Volume556,472 shs
Market Capitalization$25.37 million
P/E Ratio-0.20
Dividend YieldN/A
Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NVLN



Sales & Book Value

Annual Sales$138.44 million
Book Value$0.80 per share


Net Income$-126,710,000.00


Market Cap$25.37 million

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($0.34) by $1.42. The biotechnology company earned $27.48 million during the quarter. View Novelion Therapeutics' Earnings History.

When is Novelion Therapeutics' next earnings date?

Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Novelion Therapeutics.

What price target have analysts set for NVLN?

2 analysts have issued 12-month price targets for Novelion Therapeutics' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Novelion Therapeutics' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 273.1% from the stock's current price. View Analyst Price Targets for Novelion Therapeutics.

What is the consensus analysts' recommendation for Novelion Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novelion Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novelion Therapeutics.

Has Novelion Therapeutics been receiving favorable news coverage?

News headlines about NVLN stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Novelion Therapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.

Are investors shorting Novelion Therapeutics?

Novelion Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 454,783 shares, a decline of 26.7% from the December 31st total of 620,538 shares. Based on an average trading volume of 240,346 shares, the short-interest ratio is presently 1.9 days. Currently, 2.9% of the shares of the company are sold short. View Novelion Therapeutics' Current Options Chain.

Who are some of Novelion Therapeutics' key competitors?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:
  • Dr. Mark H. N. Corrigan, Exec. Chairman (Age 61)
  • Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Michael D. Price, Exec. VP & CFO (Age 61)
  • Mr. Roger W. Louis, Global Chief Compliance Officer & Sr. VP (Age 63)
  • Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 55)

Who are Novelion Therapeutics' major shareholders?

Novelion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (6.49%), Highbridge Capital Management LLC (5.00%), Stonepine Capital Management LLC (2.81%), Millennium Management LLC (0.60%), Geode Capital Management LLC (0.44%) and Virtu Financial LLC (0.16%). Company insiders that own Novelion Therapeutics stock include Donald K Stern, Healthcare Master Fun Broadfin and Jason Aryeh. View Institutional Ownership Trends for Novelion Therapeutics.

Which institutional investors are selling Novelion Therapeutics stock?

NVLN stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Broadfin Capital LLC and Millennium Management LLC. View Insider Buying and Selling for Novelion Therapeutics.

Which institutional investors are buying Novelion Therapeutics stock?

NVLN stock was bought by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Virtu Financial LLC and Geode Capital Management LLC. Company insiders that have bought Novelion Therapeutics stock in the last two years include Donald K Stern and Jason Aryeh. View Insider Buying and Selling for Novelion Therapeutics.

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $1.34.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $25.37 million and generates $138.44 million in revenue each year. The biotechnology company earns $-126,710,000.00 in net income (profit) each year or ($6.81) on an earnings per share basis. Novelion Therapeutics employs 180 workers across the globe.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]

MarketBeat Community Rating for Novelion Therapeutics (NASDAQ NVLN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel